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Background: Hypertension, dyslipidemia, and other cardiovascular risk factors are linked 
epidemiologically, clinically, and metabolically. Intensive/Initial Cardiovascular Examination 
regarding Blood Pressure levels, Evaluation of Risk Groups (ICEBERG) study focuses on the 
effect of dyslipidemia on cardiovascular risk evaluation and association of lipid proﬁ  le with 
other risk factors.
Patients and methods: The ICEBERG study consisted of two sub-protocols: ICEBERG-1, 
conducted at 20 university hospitals (Referral Group) and ICEBERG-2, conducted at 197 primary 
healthcare centers (Primary Care Group). Sub-protocol had two patient proﬁ  les: patients 
previously diagnosed with essential hypertension and under medical treatment (Treated Group) 
and patients with systolic blood pressure  130 mmHg or diastolic blood pressure  85 mmHg, 
with no antihypertensive treatment for at least 3 months before inclusion (Untreated Group). 
Dyslipidemia was evaluated and cardiovascular risk stratiﬁ  cation was performed according to 
ESC/ESH guidelines.
Results: More than half of the treated and untreated subjects were classiﬁ  ed into high or very 
high cardiovascular risk groups. In a total of 1817 patients, the percentage of patients in “high” 
plus “very high” added risk groups increased to 55.2% in Treated Referral Group (p   0.001), 
to 62.6% in Untreated Referral Group (p = 0.25) and to 60.7% in Untreated Primary Care Group 
(p   0.001), by re-evaluation of patients’ lipid values.
Conclusions: Serum lipid levels are useful in stratifying hypertensive patients into cardiovas-
cular risk groups more accurately, for appropriate antihypertensive treatment.
Keywords: hypertension, dyslipidemia, cardiovascular disease
Introduction
Dyslipidemia is characterized by elevated low-density lipoprotein (LDL) cholesterol, 
and triglycerides (TG), and decreased high-density lipoprotein (HDL) cholesterol. 
There is considerable evidence that hypertension (HT), dyslipidemia, and other cardio-
vascular (CV) risk factors are linked epidemiologically, clinically, and metabolically 
(Eaton et al 1994; Thomas et al 2001, 2002; O’Meara et al 2004; Liao et al 2004).
It is well known that high serum total and LDL cholesterol are particularly 
important risk factors for coronary artery disease (Brown et al 1997; Gould et al 
1998; Ballantyne 1998). Many prospective and case-control studies have shown 
a positive association between serum TG and coronary artery disease risk and 
demonstrated the importance of fasting TG level as an independent risk factor Integrated Blood Pressure Control 2008:1 6
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(Austin 1991; Hokanson and Austin 1996). A number 
of clinical trials including The Framingham Heart Study 
have concluded that a low HDL cholesterol level predicts 
the risk for coronary artery disease independently of other 
risk factors (Castelli et al 1986; Kwiterovich 1998). Each 
1 mg/dL decrease in HDL cholesterol has been shown to 
increase risk for coronary artery disease by 2% and 3% in 
men and women, respectively (Gordon et al 1989). The 
Veterans Affairs High-Density Lipoprotein Cholesterol 
Interventional Trial, investigating the impact of ﬁ  brate 
therapy on CV risk, demonstrated that 6% increase in HDL 
cholesterol was associated with a 22% decrease in coronary 
events (Rubins et al 1999).
Individuals with high blood cholesterol levels have 
a higher prevalence of HT and those with high blood 
pressure have a higher prevalence of hypercholesterolemia 
(Johnson et al 2004; O’Brien et al 2003; European Society 
of Hypertension-European Society of Cardiology Guidelines 
Committee 2003). A recent epidemiologic study revealed that 
56.5% of patients with HT also had concomitant dyslipidemia 
and the percentage of patients with HT and dyslipidemia in 
the total population was estimated to be 15% (Eaton et al 
1994). The clustering of these two conditions is important, 
because individuals with co-existing HT and dyslipidemia 
are particularly likely to develop atherosclerosis. This 
interplay is now known to produce a marked increase in 
CV disease risk (Thomas et al 2002; Liao et al 2004). The 
prevalence of stroke and peripheral arterial disease similarly 
increased among patients having both conditions (Johnson 
et al 2004).
The “Intensive/initial Cardiovascular Examination 
Regarding Blood pressure levels: Evaluation of Risk Groups 
(ICEBERG)” study aimed to determine CV risk evaluation 
and stratification of subjects with high normal or high 
blood pressure and also to evaluate the impact of different 
laboratory tests on patients’ stratiﬁ  cation. The objective of 
this article was to evaluate the serum lipid proﬁ  les of the 
ICEBERG study population, impact of lipid proﬁ  le on CV 
risk stratiﬁ  cation of patients and the association of serum 
lipid levels with other CV risk factors.
Patients and methods
Study design
ICEBERG was a healthcare organization-based epide-
miological study with two sub-protocols. ICEBERG-1 was 
conducted at 20 referral hospitals (Referral Group) and ICE-
BERG-2 was conducted at 197 primary healthcare centers 
(Primary Care Group).
Study population and procedures
Both Referral and Primary Care Groups consisted of two 
profiles of patients: risk profile A and B. Risk profile 
A consisted of patients who were under medical treatment 
for essential HT (Treated Patients). Risk proﬁ  le B included 
patients diagnosed with high-normal or high blood pressure 
[systolic blood pressure (SBP)  130 mmHg or diastolic 
blood pressure (DBP)   85 mmHg] who have not received 
any anti-hypertensive medication for at least the last 3 months 
before inclusion (Untreated Patients). Patients with secondary 
HT, pregnant patients and patients younger than 18 years of 
age were not included in the study. Signed informed consent 
was obtained from each patient who accepted to participate in 
the study. The study was approved by the Ethics Committee 
of Istanbul University, Istanbul School of Medicine.
Treated Primary Care Group patients were not analyzed 
in this article, since laboratory evaluation was not practical 
and not performed in this group, because of its largest size 
(n = 8496).
Routine clinical evaluation
All patients were evaluated initially by medical history and a 
complete physical examination. At least two sitting blood pres-
sure measurements were performed as described previously 
(O’Brien et al 2003). In addition to demographic data and 
anti-hypertensive treatment history, hypertensive risk proﬁ  le, 
concomitant diseases and target organ damage data, waist 
circumference and body mass index measurements were col-
lected as described in European Society of Cardiology Guidelines 
(2003) and routine serum and urine analysis were performed.
Evaluation of the patients’ lipid proﬁ  le
The lipid proﬁ  le of the patients was determined by measuring 
serum total cholesterol, HDL cholesterol, LDL cholesterol and TG 
levels. Dyslipidemia was diagnosed when serum total choles-
terol and LDL cholesterol levels were  250 mg/dL,  155 mg/dL, 
respectively and HDL cholesterol level was  40 mg/dL in 
men and  48 mg/dL in women (Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in 
Adults 2001). In addition, apolipoprotein-A and -B levels were 
also measured as indicators of dyslipidemia. Evaluation of 
dyslipidemia was performed in Treated and Untreated Referral 
Groups and in Untreated Primary Care Group.
Stratiﬁ  cation of patients by absolute 
cardiovascular risk factor
Regarding overall absolute CV disease risk assessment, 
European Society of Cardiology Guidelines Committee Integrated Blood Pressure Control 2008:1 7
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classified the patients into “low”, “moderate”, “high” 
and “very high” added risk groups. In the present study, 
the target organ damage was assessed by the following 
approaches: 1) routine procedures [medical history, physical 
examination, electrocardiography (ECG), serum creatinine 
and urine analysis]; 2) routine procedures along with 
subsequent reassessment by serum high sensitive C-reactive 
protein (hs-CRP) levels and urinary albumin excretion (plus 
echocardiography (ECHO) and carotid ultrasonography, in 
the Untreated Referral Group). Patient stratiﬁ  cation was 
performed separately and cumulatively by using data on 
the following: 1) medical history plus physical examina-
tion including blood pressure measurements, 2) routine 
laboratory tests (fasting blood glucose, lipid proﬁ  le, serum 
potassium, serum and urine creatinine, complete urine test), 
3) presence of microalbuminuria, 4) high plasma hs-CRP 
levels, 5) presence of left ventricular hypertrophy by ECG, 
6) presence of left ventricular hypertrophy by ECHO, 
and 7) presence of vascular end organ damage by carotid 
ultrasonography.
Statistical analysis
The statistical analyses presented the demographic, physical 
and laboratory ﬁ  ndings, the presence of risk factors, concomi-
tant diseases, target organ damage and the blood pressure 
levels in the study groups descriptively, using mean and 
standard deviation and/or median for the numeric variables 
and percent distributions for the categorical ones.
The analyses used to compare non-normally and normally 
distributed dependent variables between groups were Kruskal 
Wallis non-parametric ANOVA, Mann-Whitney U test, 
Chi-square test and Fisher’s exact test; and one-way ANOVA, 
Tukey HSD test and Student's t test, respectively. Values of 
p   0.05 were considered as statistically signiﬁ  cant.
Results
Study population proﬁ  le
The numbers of patients in Referral Group, Treated and 
Untreated study arms, were 765 (60.9% females; mean 
age 58.4 ± 10.4 years) and 164 (56.4% females; mean 
age 50.1 ± 11.3 years), and in Untreated Primary Care 
Group, 888 (54.9% females; mean age 51.1 ± 12.1 years), 
respectively.
The most common risk factors were abdominal obesity 
(72.2%), sedentary life style (62.8%), age ( 55 for 
men,  65 for women) (30.4%), and hs-CRP ( 1 mg/dL) 
(50.4%) and the most common concomitant diseases were 
heart disease (22.0%) and diabetes mellitus (20.4%). 
In terms of renal disease, 9.0%, 5.5% and 6.0% of Treated 
Referral, Untreated Referral and Untreated Primary Care 
patients, respectively, have renal disease according to 
laboratory ﬁ  ndings (ie, slight increase in serum creatinine 
level, presence of proteinuria). For Treated patients, mono-
therapies with the angiotensin converting enzyme (ACE) 
inhibitors, calcium channel blockers, angiotensin receptor 
blockers, diuretics or B-adrenergic blockers and combined 
therapies with the angiotensin receptor blockers + diuret-
ics or ACE inhibitors + calcium channel blockers were 
the most commonly prescribed antihypertensive therapies. 
Table 1 summarizes the major population characteristics 
in study groups.
Blood pressure measurements 
and severity of hypertension
The patients were stratified into different degrees of 
increased blood pressure according to European Society 
of Cardiology Guidelines (2003) (Figure 1A). The 
patients in all groups were stratified into high normal 
(SBP 130–139 mmHg and/or DBP 85–89 mmHg), 
Grade 1 (mild) HT (SBP 140–159 mmHg and/or DBP 
90–99 mmHg), Grade 2 (moderate) HT (SBP 160–179 mmHg 
and/or DBP 100–109 mmHg), Grade 3 (severe) HT 
(SBP   180 mmHg and/or DBP   110 mmHg), isolated 
systolic HT (SBP   140 mmHg and DBP   90 mmHg).
The distribution of patients to different blood pressure 
groups was significantly different among sub-groups 
(p   0.001). As could be expected, the percentage of patients 
with Grade 3 HT was smallest in Treated Referral group.
Evaluation of dyslipidemia according 
to serum lipid proﬁ  le
As given in Table 2, 45.8% (41.8% males, 48.5% females) of 
the Treated Referral, 42.5% (40.3% males, 44.6% females) 
of the Untreated Referral and 47.6% (43.1% males, 51.4% 
females) of the Untreated Primary Care patients had dyslip-
idemia according to laboratory results. The percentages of 
patients having dyslipidemia according to history in the same 
study groups were 39.9% (35.2% males, 43.1% females), 
18.9% (19.7% males, 18.5% females) and 19.4% (17.8% 
males, 20.6% females), respectively. Thus, dyslipidemia 
was diagnosed in a total of 65.0% of the Treated patients 
(Referral) and 54.6% of the Untreated patients (both Referral 
and Primary Care). In a total of 29.2% of patients who 
had dyslipidemia according to history, 20.6% of them had 
elevated total cholesterol, 9.2% had elevated LDL cholesterol 
and 6.8% had reduced HDL cholesterol levels.Integrated Blood Pressure Control 2008:1 8
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Among all patients, 5.9% (6.5% males, 5.5% females) of 
them were currently using antilipidemic drugs. The percent-
ages of patients using antilipidemic drugs were as follows: 
12.5% in Treated Referral, 0.6% in Untreated Referral, and 
2.1% in Untreated Primary Care study groups.
Association between serum lipid proﬁ  le 
and other cardiovascular risk factors
As shown in Table 3, serum total cholesterol levels correlated 
with blood pressure values, obesity parameters (ie, body 
mass index and waist circumference) and microalbuminura 
in Treated Referral patients. On the other hand, total serum 
cholesterol level correlated with only systolic pressure 
in Untreated patients. LDL cholesterol levels revealed a 
positive correlation with blood pressure values and obesity 
parameters in Treated Referral patients but no correlation was 
observed in Untreated patients (Table 3). HDL cholesterol 
levels showed negative correlations with waist circumference 
and hs-CRP levels in both Treated and Untreated patients 
(Table 3). HDL cholesterol levels also correlated negatively 
with ECG and ECHO parameters (Sokolow index and left 
ventricular mass index values, respectively) as indicators 
of left ventricular hypertrophy in these patients. Serum TG 
levels correlated positively with almost all other CV risk 
Table 1 The mean age, gender distribution and percentages of patients with the most common risk factors and concomitant diseases 
in the study groups. Data are given as mean ± standard deviation
Referral groups Primary Care group
  Treated (n = 765) Untreated (n = 164) Untreated (n =888)
Age (years) 58.4 ± 10.4 50.1 ± 11.3 51.1 ± 12.1
Gender (F/M) 464/298 92/71 485/398
Physical ﬁ  ndings
 SBP  (mmHg) 142.5 ± 21.1 154.6 ± 18.4 158.0 ± 19.9
 DBP  (mmHg) 86.1 ± 11.1 93.9 ± 10.6 96.3 ± 10.7
 BMI  (kg/m2) 29.3 ± 4.9 28.4 ± 4.4 29.1 ± 4.9
 Waist  circumference  (cm)
 Males 99.3 ± 11.9 99.9 ± 14.0 99.5 ± 12.5
 Females 99.0 ± 14.3 93.2 ± 12.5 98.5 ± 14.0
Percentage of patients with dyslipidemia 
according to medical history
  Increased total cholesterol 25.6% 12.2% 11.8%
  Increased LDL cholesterol 16.2% 6.7% 5.0%
  Reduced HDL cholesterol 8.2% 1.8% 5.6%
Percentage of patients with dyslipidemia 
according to lipid proﬁ  le
  Increased total cholesterol 9.2% 11.3% 11.7%
  Increased LDL cholesterol 11.0% 11.3% 13.5%
  Reduced HDL cholesterol 35.8% 302% 35.6%
Percentage of patients with risk factors 
or concomitant diseases
 Age  ( 55 for men;  65 for women) 40.2% 25.6% 22.7%
 Smoking 15.4% 20.1% 23.9%
 Alcohol  consumption 7.5% 10.4% 12.2%
  Sedentary life style 61.4% 59.8% 64.6%
 hs-CRP  ( 1 mg/dL) 48.9% 57.6% 55.1%
 Abdominal  obesity 74.5% 61.3% 72.3%
 Heart  disease 37.9% 20.7% 8.4%
 Diabetes  mellitus 22.7% 15.6% 19.2%
 Renal  disease 9.0% 5.5% 6.0%
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein.Integrated Blood Pressure Control 2008:1 9
Dyslipidemia and cardiovascular risk stratiﬁ  cation
factors in Treated patients whereas in Untreated patients 
only obesity parameters and hs-CRP levels correlated with 
TG levels signiﬁ  cantly (Table 3).
Impact of serum lipid proﬁ  le 
on cardiovascular risk stratiﬁ  cation
The patients in study groups were stratiﬁ  ed into CV risk 
groups according to European Society of Cardiology 
Guidelines (2003) regarding existing risk factors in 
history and concomitant diseases before additional tests 
(Figure 1B). There were signiﬁ  cant differences between 
sub-groups regarding distribution of patients into different 
risk groups (p   0.001). More than half of the treated and 
untreated subjects were classiﬁ  ed into high or very high 
cardiovascular risk groups. Patients with “high” plus “very 
high” added risk was signiﬁ  cantly higher in Untreated 
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Figure 1 Distribution of patients in study groups into different grades of hypertension (A) and into CV risk groups according to existing risk factors before additional tests (B). 
Distribution into different groups showed signiﬁ  cantly different patterns for both panels (p   0.001, by Kruskal-Wallis test). Group comparisons were as follows: (A) p   0.001 
for Treated Referral Group vs other groups; p = 0.001 for Untreated Referral vs Untreated Primary Care Groups; (B) p   0.001 for Treated Referral vs Untreated Primary 
Care groups, and p = 0.06 for Treated vs Untreated Referral Groups by Mann-Whitney U test.
Table 2 The serum lipid proﬁ  le of patients in study groups
Referral groups   Primary care group
Treated (n = 749–470) Untreated (n = 160–119) p value Untreated (n = 870–540)
Total cholesterol (mg/dL)
 Males 187.7 ± 39.6 196.8 ± 40.8 203.0 ± 50.3
 Females 200.2 ± 40.8 206.9 ± 43.4 0.041 204.1 ± 42.8
LDL cholesterol (mg/dL)
 Males 111.4 ± 33.0 117.6 ± 32.3 119.3 ± 34.6
 Females 118.4 ± 32.3 122.8 ± 34.2 0.08 119.1 ± 35.5
HDL cholesterol (mg/dL)
 Males 44.2 ± 10.8 47.2 ± 12.3 44.3 ± 9.2
 Females 52.4 ± 12.8 54.8 ± 13.2 0.035 51.4 ± 13.7
Triglyceride (mg/dL)
 Males 167.5 ± 117.0 164.7 ± 109.4 192.3 ± 130.4
 Females 151.0 ± 85.5 144.0 ± 88.1 0.58 160.3 ± 108.6
Apolipoprotein-A (mg/dL)
 Males 147.5 ± 29.1 155.5 ± 27.6 152.4 ± 26.3
 Females 168.1 ± 33.7 174.3 ± 29.8 0.07 168.9 ± 32.5
Apolipoprotein-B (mg/dL)
 Males 95.2 ± 27.5 102.8 ± 28.8 101.1 ± 26.3
 Females 99.5 ± 28.3 99.3 ± 25.7 0.27 98.9 ± 30.9
Notes: Data are given as mean ± standard deviation. P values indicate the statistical difference between Treated and Untreated Referral Groups.Integrated Blood Pressure Control 2008:1 10
Kabakci et al
Groups (Referral + Primary Care) compared to Treated 
Group (Referral) (p   0.001).
The ratios of patients in “high” plus “very high” added 
risk groups assessed by medical history and physical 
examination were 51.2%, 60.7% and 54.2% in Treated 
Referral, Untreated Referral and Untreated Primary Care 
patients, respectively. Upon stepwise re-stratiﬁ  cation, 
the percentage of patients in “high” plus “very high” 
added risk groups increased to 55.2% in Treated Referral 
Group (p   0.001), to 62.6% in Untreated Referral Group 
(p = 0.25) and to 60.7% in Untreated Primary Care Group 
(p   0.001), by re-evaluation with patients’ serum lipid 
values (Figure 2). When all risk groups are considered, 
additional shifts to upper risk group by including lipid 
proﬁ  le data to medical history were 5.5% in Treated 
Referral, 3.7% in Untreated Referral, and 9.3% in 
Untreated Primary Care Groups.
Discussion
Patients with multiple CV risk factors are at much greater 
risk for CV disease-related events than those with a single 
factor. Abnormalities in plasma lipoprotein metabolism play 
a central role in the pathogenesis of atherosclerosis, and arte-
rial HT with elevated systolic or diastolic blood pressure is 
positively and independently associated with coronary heart 
disease (Shurtleff 1970; SHEP Cooperative Research Group 
1991). Data from the Framingham Study demonstrated that 
HT tends to occur in association with other atherogenic risk 
factors (eg, 78% of hypertensive men and 82% of hyperten-
sive women had multiple CV risk factors) (Kannel 2000).
Table 3 Correlation between lipid proﬁ  le and other cardiovascular risk factors in study groups
Treated (Referral) Untreated (Referral and 
primary care)
 rp rP
Total cholesterol
  Systolic blood pressure 0.124  0.001 0.073 0.019
  Diastolic blood pressure 0.123  0.001 0.037 0.240
  Body mass index 0.048 0.001 0.037 0.244
 Waist  circumference 0.030 0.047 0.053 0.109
 Microalbuminuria  (qualitative) 0.043 0.006 – –
LDL cholesterol
  Systolic blood pressure 0.074  0.001 0.042 0.179
  Diastolic blood pressure 0.071  0.001 0.034 0.284
  Body mass index 0.042 0.012 0.041 0.194
 Waist  circumference 0.045 0.010 0.064 0.053
HDL cholesterol
 Waist  circumference –0.038 0.027 –0.119  0.001
 Microalbuminuria  (qualitative) –0.073  0.001 ––
 Microalbuminuria  (quantitative) –0.104 0.005 –0.025 0.425
 hs-CRP –0.088 0.001 –0.128  0.001
 Sokolow  index –0.121 0.002 –0.052 0.156
  Left ventricular mass index – – –0.254 0.002
Triglyceride
  Systolic blood pressure 0.062  0.001 0.020 0.533
  Diastolic blood pressure 0.070  0.001 0.023 0.454
  Body mass index 0.075  0.001 0.110  0.001
 Waist  circumference 0.093  0.001 0.159  0.001
 Microalbuminuria  (qualitative) 0.079  0.001 ––
 Microalbuminuria  (quantitative) 0.120 0.001 0.057 0.076
 hs-CRP 0.047 0.075 0.114  0.001
Abbreviation: hs-CRP, high sensitivity C-reactive protein.Integrated Blood Pressure Control 2008:1 11
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This report presents the data of ICEBERG study which 
has been conducted in patients with high normal/high blood 
pressure levels either under hypertensive treatment or not 
and focuses on the evaluation of dyslipidemia as a CV risk 
factor. The diagnosis of dyslipidemia was based on the 
patients’ medical history and measured serum lipid proﬁ  le 
values. The data revealed that a total of 65.0% of the Treated 
and 54.6% of the Untreated patients had dyslipidemia. In all 
study groups, the majority of the patients had a reduced 
HDL cholesterol level. This ﬁ  nding is in accordance with 
the data of the TEKHARF cohort of 2001/02 which revealed 
prevalence of low HDL cholesterol level as 64% and 35.5% 
in men and women, respectively (Onat et al 2003). Elevated 
LDL cholesterol and triglyceride levels were the second and 
the third most common impaired lipid status, respectively. 
Among all patients, only 5.9% of them were currently using 
antilipidemic drugs.
The risk of CV disease associated with the presence of 
concomitant HT and dyslipidemia has been demonstrated 
to be greater than the sum of the CV risks for HT and dys-
lipidemia alone (Borghi 2002). Gaziano et al (1999) noted a 
potential interaction between elevated cholesterol and HT in 
the development of myocardial infarction. Thus, the need to 
quantify a person’s overall CV risk is of great importance.
In a recent retrospective cohort study aiming to estimate 
the prevalence of concurrent HT and dyslipidemia among 
a veteran population and to compare the prevalence of CV 
disease among groups with isolated versus concurrent HT 
and dyslipidemia, it has been found that 57.8% of all patients 
had HT or dyslipidemia and that nearly one third (30.7%) of 
all patients had both (Johnson et al 2004). Moreover, patients 
with these two conditions were found to have 3 to 4 times the 
prevalence of myocardial infarction than patients with either 
condition alone, and 2 to 3 times the prevalence of coronary 
artery disease, peripheral arterial disease and cerebrovascular 
disease (Johnson et al 2004).
Estimates from the National Health and Nutrition Exami-
nation Survey III found that the prevalence of HT was 32.8% 
and the proportion of patients with LDL cholesterol above 
130 mg/dL was 49% for men and 43% for women (American 
Heart Association 2003). Johnson et al have found a 52.1% 
prevalence of HT and a 36.3% prevalence of dyslipidemia 
in their study populations (Johnson et al 2004).
In the current study, the analysis of the correlation 
of serum lipid proﬁ  le with other major CV risk factors 
demonstrated statistically signiﬁ  cance at different levels. 
Impairment of the lipid profile mostly correlated with 
elevated blood pressure levels (systolic and/or diastolic) 
Cardiovascular Risk Stratification by HPE versus HPE +lipid profile
%
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Figure 2 The percentages of Treated, Untreated Referral and Untreated Primary Care patients in “high” plus “very high” added risk groups according to medical history and 
physical examination (HPE), and medical history and physical examination plus serum lipid proﬁ  le (plus lipid proﬁ  le). ***p   0.001 vs HPE (McNemar test).Integrated Blood Pressure Control 2008:1 12
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and with obesity parameters (body mass index and/or waist 
circumference). Signiﬁ  cant correlations between reduced 
HDL cholesterol and microalbuminuria, hs-CRP and 
left ventricular hypertrophy parameters are of particular 
importance. Although correlation coefﬁ  cients (r values) are 
relatively low and statistical signiﬁ  cance might be due to 
large sample size, our observations are in accordance with 
the ﬁ  ndings of Castelli and Anderson who noted that blood 
pressure and serum cholesterol were strongly correlated 
among hypertensive patients and recommended early treat-
ment of hypercholesterolemia in patients with HT (Castelli 
and Anderson 1986).
The other important observation of our study was that 
when we included lipid proﬁ  le data to CV risk stratiﬁ  cation 
in addition to routine clinical evaluation with medical history 
and physical examination, we observed marked upward shifts 
to “high and very high added risk” groups in all study groups. 
Moreover, when all risk groups were considered, we observed 
marked additional shifts to upper risk group by including lipid 
proﬁ  le data to routine clinical evaluation in all study groups. 
These observations may suggest that the use of serum lipid 
data in screening is useful in stratifying patients with high 
normal and high blood pressure levels into risk groups at 
both Referral and Primary Health Care settings.
Recent studies have suggested that substantial reductions 
in the risk of coronary heart disease, stroke, and death can be 
achieved by targeting HT and dyslipidemia (Wald and Law 
2003; Wong et al 2003). For instance, it has been estimated 
that 79% of ischemic heart disease events and 69% of strokes 
would be prevented if LDL cholesterol levels decreased by 
70 mg/dL and diastolic pressure by 11 mmHg (Wald and 
Law 2003).
As a conclusion, an important fraction of ICEBERG 
patients with high normal and high blood pressure levels, 
either under antihypertensive therapy or not was found to 
have dyslipidemia. The serum lipid proﬁ  le of these patients 
correlated signiﬁ  cantly with other major CV risk factors. 
These observations taken together with the data demonstrat-
ing the importance of dyslipidemia in patients’ risk strati-
ﬁ  cation imply that patients who have high blood pressure 
and impaired lipid proﬁ  le are at high risk and should be the 
target of aggressive primary preventive strategies to reduce 
the burden of HT and subsequent CV disease.
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and nephrology department of Hacettepe University.
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